AstraZeneca Heart Drug Fails Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca detailed the failure of its Phase 3 trial for an experimental silencer drug in ATTR-CM patients, finding no additional clinical benefit when added to existing stabilizer therapy
- ATTR-CM patients in the trial showed no improvement from AstraZeneca’s silencer drug, largely because most were already taking a stabilizer medication that appeared to dominate therapeutic effect
- Ionis Pharmaceuticals, AstraZeneca’s development partner on the silencer drug, faces setbacks as the trial outcome undermines the potential market differentiation of silencer-based therapies
- Alnylam Pharmaceuticals markets another silencer drug for ATTR-CM, and analysts now suggest the trial results may weaken the positioning of similar injectable RNA-targeted treatments
- BridgeBio manufactures a new stabilizer drug for ATTR-CM, and the trial outcome has strengthened analysts’ views that oral stabilizers could be superior to injectable silencers
Why it matters: The trial failure shifts momentum toward stabilizer drugs, which are oral and easier to administer, potentially reducing market opportunities for silencer drugs from AstraZeneca, Ionis, and Alnylam. With most patients already benefiting from stabilizers, the bar for new therapies to show added value has risen materially.
Ask SkimNews
